Results 141 to 150 of about 2,398,416 (309)
The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers
Molecular Oncology, EarlyView.The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce +11 more
wiley +1 more source
[Texas Instruments Press Releases, March-May 1969]
, 1969 1. Press release dated March 10, 1969 announces price reductions on certain preferred semiconductor devices. A listing of prices, comments on the price reduction program, and list of preferred types and the devices which they replace follow. 2.
Texas Instruments Incorporated
core
Molecular Oncology, EarlyView.In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge +17 more
wiley +1 more source
[Texas Instruments Press Releases, October 1966]
, 1966 1. Release dated October 4, 1966 announces that TI's offering of 599,031 shares of common stock was 93.4% subscribed, with the remaining shares to be underwritten by a group headed by Morgan Stanley & Co. 2.
Texas Instruments Incorporated
core
Molecular Oncology, EarlyView.In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera +11 more
wiley +1 more source
[Texas Instruments Press Releases, March 1970]
, 1970 1. Press release dated March 2, 1970 is in regard to TI's annual sales and earnings report for 1969. It includes a consolidated financial summary. 2. Press release dated March 2, 1970 announces the appointment of Richard W. Renzetti as President of Texas
Texas Instruments Incorporated
core
KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer
Molecular Oncology, EarlyView.Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan +16 more
wiley +1 more source
[Texas Instruments Press Releases, July-August 1962]
, 1962 1. Release dated July 5, 1962 announces that Instruments Incorporated will build and operate a seismological observatory near McMinnville, Tennessee as part of a $2.2 million Project VELA UNIFORM contract. 2.
Texas Instruments Incorporated
core
Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer
Molecular Oncology, EarlyView.Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley +1 more source